Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe

An excellent paper distributed highlighting the utility of patient registries for informing regulatory authorities on rare disease medicinal products: https://t.co/o5VLtnxker #patientregistries #realworlddata #raredisease

Treatment development for #rarediseases can face significant barriers when it comes to generating enough #realworlddata. This article gives an overview of the increasing significance of #patientregistries in overcoming these barriers. Read more: https://t

"Patient registries have been recognised as important sources of data on healthcare practices, drug utilisation and clinical outcomes." This particularly true for rare disease treatment development. How do they help accomplish this? Read the article: http

📚-tip: Using #registry data to support #regulatory decision-making. This interesting article by Carla R. Jonker @EMA_News presents use cases and discusses possibilities and limitations. https://t.co/7ztVb3N4To https://t.co/vrmrwRb4ir